United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF C United States Patent and Trademark O Address: COMMISSIONER FOR PATENTS	fice
P.O. Box 1450 Alexandria, Virginia 22313-1450	
www.uspto.gov	

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/717,868		11/19/2003	Ingo Konetzki	1/1428	9343
28501	28501 7590 02/17/2006			EXAMINER	
MICHAEL P. MORRIS			SEAMAN, D MARGARET M		
BOEHRINGER INGELHEIM CORPORATION 900 RIDGEBURY ROAD			ART UNIT	PAPER NUMBER	
P. O. BOX 368			1625		
RIDGEFIELD, CT 06877-0368			DATE MAILED: 02/17/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/717,868	KONETZKI ET AL.			
Office Action Summary	Examiner	Art Unit			
	D. Margaret Seaman	1625			
- The MAILING DATE of this communication app	_				
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirn vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 28 No	ovember 2005.				
·= · ·	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.			
Disposition of Claims					
4) Claim(s) 1-15 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-15</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	r election requirement.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the E	Examiner.			
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau					
* See the attached detailed Office action for a list	or the certified copies not receive	a.			
Attachment(s)					
Notice of References Cited (PTO-892)	4) Interview Summary				
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) ☑ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal P	ate atent Application (PTO-152)			
Paper No(s)/Mail Date	6) Other:	,			

Application/Control Number: 10/717,868 Page 2

Art Unit: 1625

DETAILED ACTION

This application was filed 11/19/2003 and claims benefit of Provisional Application 60/446,668 (2/11/2003) which claims benefit of Germany 102 56 080 (11/29/2002). Claims 1-15 are before the Examiner.

Claim Rejections - 35 USC § 112

1. Claim 9 remains rejected under 35 U.S.C. 112, second paragraph, as stated in paper dated 6/13/2005, because claim 9 still remains drawn to a composition of formula 1 and formula 2. Correction is required.

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Application/Control Number: 10/717,868 Page 3

Art Unit: 1625

3. Claims 1-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 02/45703 and WO 00/75114.

WO 02 teaches the combination of two active ingredients to treat obstructive or inflammatory airway disease. WO 02 teaches propellants, inhalable forms, dispersions, nebulizers, particle size and weight ratios. The first compound of the combination is the compound of the instantly claimed formula 2'. The second is a corticosteroid, which is not the instantly claimed formula 1, but which is in the same family as the instantly claimed formula 1.

WO 00 teaches compounds of formula (I) that encompass the instant claimed formula 2' to treat obstructive or inflammatory airway diseases in combination with other active ingredients such as tiotropium bromide (see page 17) for use as an inhalant or solid drug. WO00 does not specifically teach the instant compound of formula 2' but teaches formula (I) with a small Markush using formula (III) that would make the instant compound obvious.

WO 02 teaches a combination of two active ingredients to treat obstructive or inflammatory airway diseases.

It would have been obvious to one of ordinary skill in the art to use the compound of the instantly claimed formula 2' as taught by WO 02 with a tiotropium (instantly claimed formula 1) as taught by WO 00 to treat obstructive or inflammatory airway diseases. Rationale: WO 00 teaches a Markush that encompasses the instantly claimed formula 2' plus tiotropium to treat obstructive or inflammatory airway diseases and WO 02 teaches the instant claimed 2' in combination with another active ingredient to treat obstructive or inflammatory airway diseases.

Art Unit: 1625

The combination of the two references would have been within the skill of the ordinary artisan without the use of hindsight.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. Margaret Seaman whose telephone number is 571-272-0694. The examiner can normally be reached on 730am-4pm, Monday-Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecelia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197/(toll-free).

D. Margaret Seaman Primary Examiner Art Unit 1625

dms